Immunotherapy and targeted therapies for melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, from Institut Gustave Roussy, Villejuif, France, reviews the results of the phase 3 CheckMate 067 trial of nivolumab in treatment-naive patients with advanced melanoma, and the phase 3 COMBI-d trial, which compared the combination of dabrafenib and trametinib versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive melanoma.

Share this video  
Similar topics